Elon Musk's X sues New York over social media hate speech law
Elon Musk's X sues New York over social media hate speech law
Show Caption
Hide Caption
Six takeaways from the President Donald Trump, Elon Musk feud
From disappointment to threats, here are six takeaways from the public spat between President Donald Trump and Elon Musk.
Elon Musk's X Corp sued New York on Tuesday, challenging the constitutionality of a state law requiring social media companies to disclose how they monitor hate speech, extremism, disinformation, harassment and foreign political interference.
X said the law known as the Stop Hiding Hate Act violated the First Amendment and state constitution by subjecting it to lawsuits and heavy fines unless it disclosed "highly sensitive and controversial speech" that New York may find objectionable.
Deciding what content is acceptable on social media platforms "engenders considerable debate among reasonable people about where to draw the correct proverbial line," X said. "This is not a role that the government may play."
The complaint filed in Manhattan federal court also quoted a letter from two legislators who sponsored the law, which said X and Musk in particular had a "disturbing record" on content moderation "that threatens the foundations of our democracy."
New York Attorney General Letitia James, a Democrat who enforces the state's laws, is the named defendant in X's lawsuit. Her office did not immediately respond to requests for comment.
Musk, the world's richest person and recently a close adviser to Republican President Donald Trump, has described himself as a free speech absolutist.
In case you missed it: Elon Musk vastly outranks all other 'superbillionaires' in new report on richest people
He did away with the content moderation policy of Twitter, as X was previously known, after he bought the company for $44 billion in October 2022.
New York's law requires social media companies to disclose steps they take to eliminate hate on their platforms, and to report their progress. Civil fines could reach $15,000 per violation per day.
The law was written by state Senator Brad Hoylman-Sigal and Assemblymember Grace Lee, both Democrats, with help from the Anti-Defamation League. It was signed in December by Governor Kathy Hochul, also a Democrat.
X said New York based its law on a nearly identical 2023 California law whose enforcement was partially blocked by a federal appeals court last September because of free speech concerns.
California agreed in a February settlement with X not to enforce the law's disclosure requirements.
In a joint statement, Hoylman-Sigal and Lee said they were confident a judge would uphold New York's content moderation law.
"The fact that Elon Musk would go to these lengths to avoid disclosing straightforward information to New Yorkers" shows why the law is necessary, the legislators said.
The case is X Corp v James, U.S. District Court, Southern District of New York, No. 25-05068.
Reporting by Jonathan Stempel in New York; Editing by Chizu Nomiyama, Bill Berkrot and Nick Zieminski
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Move Over Hims & Hers Health: This Insurance Business Could Be the Next Monster Healthcare Stock (Hint: It's Not UnitedHealth)
Telemedicine company Hims & Hers Health has been one of the hottest healthcare stocks in recent memory. Changes at UnitedHealth Group have attracted the attention of investors, but a smaller player called Oscar Health is the one to pay attention to. Oscar Health's business model and approach are similar to Hims & Hers, and it seeks to disrupt legacy insurers. 10 stocks we like better than Oscar Health › When it comes to healthcare stocks, many investors pay attention to the usual suspects: Eli Lilly, Novo Nordisk, CVS Health, or Johnson & Johnson. These companies have built up enormous brand equity thanks to blockbuster drugs and widely recognized pharmacy management services. With the exception of CVS, whose shares have risen 46% so far this year, none of the other companies have generated robust stock price returns so far in 2025. Lilly, Novo, and Johnson & Johnson are seeing share price pressure over concerns that President Donald Trump's administrative actions could impact the pharmaceutical industry -- particularly as it relates to tariffs and medication pricing. One healthcare player that is (so far) outmaneuvering investor trepidation throughout 2025 is telemedicine company (NYSE: HIMS). Its share price is up 138% in 2025 (as of June 17). While buying into Hims and Hers stock to follow the momentum is tempting, I think a different, dirt cheap health insurance stock is positioned for a breakout akin to Hims & Hers Health. And no, I'm not talking about the beaten-down UnitedHealth Group. Rather, I think Oscar Health (NYSE: OSCR) could be the next big multibagger in healthcare stocks. Curious? Read on to learn more about Oscar Health and why I'm so bullish on the stock. When it comes to accessing patient care, consumers have a couple of options. On one hand, they can take time to go to brick-and-mortar retailers like CVS to fulfill a prescription or take the time to schedule an appointment and wait in a busy doctor's office. Alternatively, they can streamline their efforts by using Hims & Hers telemedicine services to gain back some time (and possibly some money) while still accessing necessary health services and medications. This technology-first approach has served Hims well, particularly as it relates to acquiring customers across younger demographics such as Millennials and Gen-Z. This approach is by design as younger patients tend to be more receptive to the idea of accessing critical information (i.e., patient care) online as opposed to the traditional, time-consuming methods that include finding a doctor in your network, making an appointment, and waiting. Oscar is using a similar approach to transform access to health insurance. The company hopes to capture a strategic lead over competitors with a tech-first digital platform. While some legacy insurers have also invested in technology infrastructure, they did so by retrofitting archaic and antiquated manual processes into a technology platform that likely doesn't fit well with their original business models. Another important item to note is that Hims & Hers does not offer as comprehensive a service as going to a traditional doctor. In other words, Hims & Hers currently focuses on a handful of treatments across specific segments like mental health, sexual health, and weight management. Likewise, Oscar has a niche focus on Affordable Care Act (ACA) members and small employers that aren't covered by legacy health insurance providers. While Oscar's upside might appear limited given its niche focus, a look at its metrics suggests it still has some strong growth prospects. Despite an intense competitive landscape in the health insurance market, Oscar has identified pockets that it can dominate, as evidenced by the steepening slope of the revenue line over the last five years, coupled with rising cash flow and liquidity. The biggest risk surrounding Oscar right now has to do with potential changes in the regulatory landscape as it pertains to the ACA. While policy changes could put some pressure on Oscar's core business, the company is working to diversify its revenue stream by expanding into related markets -- just as Hims & Hers has done in recent years by getting into the weight management space, competing with the likes of Lilly and Novo. Data that Oscar Health recently provided to investors shows that its primary market of traditional ACA members totals roughly 21 million. However, by expanding into individual coverage health reimbursement arrangements (ICHRAs) with small and medium-sized businesses (SMB), Oscar could open up its total customer pool to 75 million -- growing its total addressable market (TAM) from $160 billion today to $720 billion. This expansion effort should help keep the company's growth prospects on track. Given that Oscar Health's modest market capitalization of just $4 billion is roughly in line with its cash balance, it would seem that Wall Street isn't placing much value on the company's insurance business. I suspect the market may be pricing in the potential for significant downside from changes to the ACA. It may also have some skepticism about the company's pursuit of ICHRAs with small businesses. This suggests another parallel between what Oscar is trying to achieve and what Hims was building during its early days. At the start, Hims faced some doubts over customer acquisition, subscriber retention, and its ability to truly compete with larger, legacy patient care providers. But look at Hims & Hers' share price gains now. Some of those gains are rooted in a turning-of-the-page bullish narrative from some pockets of the investment community. To be clear, there are potential near-term headwinds at Oscar, but I find the long-term vision is compelling. I'm cautiously optimistic that the company has what it takes to build, grow, and sustain a diversified healthcare platform -- just as Hims & Hers has done -- and that shares will see a sharp rise sooner than some may be anticipating. Before you buy stock in Oscar Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Oscar Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,821!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $886,880!* Now, it's worth noting Stock Advisor's total average return is 791% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adam Spatacco has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends CVS Health, Johnson & Johnson, Novo Nordisk, and UnitedHealth Group. The Motley Fool has a disclosure policy. Move Over Hims & Hers Health: This Insurance Business Could Be the Next Monster Healthcare Stock (Hint: It's Not UnitedHealth) was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Gold price today, Wednesday, June 18, 2025: Gold opens strong ahead of Fed projections
Gold (GC=F) futures opened at $3,409 per ounce Wednesday, up 0.7% from Tuesday's close of $3,386.60. The price of gold has opened above $3,400 three times this month but has stopped short of beating its all-time high of $3,485.60, set in April. Economic and geopolitical factors favor ongoing gold demand. Conflict in the Middle East, plus President Donald Trump's changing tariff demands, create uncertain outlooks for oil prices, inflation, and the overall health of the U.S. economy. While stock prices are still up for the year, investors may react to the Fed's Summary of Economic Projections, to be released Wednesday. Any sign the Fed expects rates to remain high this year could trigger lower stock prices. Gold demand, and thus gold prices, typically rise when investors are pessimistic about stocks. The opening price of gold futures on Wednesday is up 0.7% from Tuesday's close of $3,386.60 per ounce. Wednesday's opening price marks a gain of 2.4% over the past week, compared to the opening price of $3,328 on June 11. In the past month, the gold futures price has risen 5.6% compared to the opening price of $3,227.70 on May 16. In the past year, gold is up 47.5% from the opening price of $2,311.80 on June 18, 2024. Don't forget you can monitor the current price of gold on Yahoo Finance 24 hours a day, seven days a week. Want to learn more about the current top-performing companies in the gold industry? Explore a list of the top-performing companies in the gold industry using the Yahoo Finance Screener. You can create your own screeners with over 150 different screening criteria. As we've been saying all week, investing in gold is a four-step process, and today, we'll explore step 3, choosing a form. Once you define your target gold allocation, you must choose a form of gold to hold. Your three options are: Physical gold Gold mining stocks Gold ETFs Physical gold includes jewelry, gold bars, and gold coins. The advantages of physical gold include: Readily accessible for use. If you keep your physical gold at home, it is easily available for you to use as a medium of exchange in an economic emergency. No added volatility or ongoing fees. Gold mining stocks tend to rise and fall with gold prices, and business-related factors enhance their volatility. Gold ETFs charge administrative fees in the form of expense ratios. Learn more: Take a deeper dive into the gold sector The disadvantages of physical gold include: Risk of theft or loss. Physical gold must be properly secured. Whether you store it in your home or with a depository, gold can be stolen. Lower liquidity. Physical gold is less liquid than stocks or ETFs. If you are not using the gold as a medium of exchange, you may need to locate a dealer and pay a markup on the sale. Owning shares in gold mining stocks provides indirect gold exposure. The advantages of mining stocks over physical gold include: Greater liquidity. Large-cap gold mining stocks like Barrick Gold Corporation (GOLD) and Franco-Nevada Corporation (FNV) generally enjoy a narrow bid-ask spread, which is a sign of liquidity. The bid-ask spread is the difference between what buyers will pay and what sellers will accept. Easy to store. Stocks live in your brokerage account and do not consume physical space. In normal times, this is an advantage. In an economic catastrophe, this could be a disadvantage if brokers or the stock market are temporarily shut down. Learn more: The top performing companies in the gold industry The disadvantages of owning gold mining stocks include: Greater volatility. Since 2000, gold mining stocks have risen and fallen faster than gold spot prices. And in recent years, gold mining stocks have trended down even as gold has gained value. No utility as a medium of exchange. Gold mining stocks can appreciate, but they have no direct utility as a medium of exchange. Gold ETFs are funds that invest in gold mining stocks or physical gold. Their advantages include: Easy to store. Like gold mining stocks, ETF shares are essentially digital assets with no storage requirements. Greater liquidity. Shares of the most popular gold ETFs, like SPDR Gold Shares ($GLD), are heavily traded which implies good liquidity. Tied directly to gold prices. ETFs backed by physical gold can be less volatile than gold mining stocks or gold mining ETFs. The disadvantages of gold ETFs include: Fund fees. Funds charge fees, which dilute returns over time. For context, the expense ratio of SPDR Gold Shares is 0.40%. This translates to $4 in fees annually for every $1,000 invested. No utility as a medium of exchange. As with gold mining stocks, you probably cannot use ETF shares to trade for food in an economic emergency. Whether you're tracking the price of gold since last month or last year, the price-of-gold chart below shows the precious metal's steady upward climb in value. Historically, gold has shown extended up cycles and down cycles. The precious metal was in a growth phase from 2009 to 2011. It then trended down, failing to set a new high for nine years. In those lackluster years for gold, your position will negatively impact your overall investment returns. If that feels problematic, a lower allocation percentage is more appropriate. On the other hand, you may be willing to accept gold's underperforming years so you can benefit more in the good years. In this case, you can target a higher percentage. The precious metal has been in the news lately, and many analysts are bullish on gold. In May, Goldman Sachs Research predicted gold would reach $3,700 a troy ounce by year-end 2025. That would equate to a 40% increase for the year, based on gold's January 2 opening price of $2,633. Rising demand from central banks, along with uncertainty related to changing U.S. tariff policy, are the factors driving the increase. If you are interested in learning more about gold's historical value, Yahoo Finance has been tracking the historical price of gold since 2000.
Yahoo
34 minutes ago
- Yahoo
ICE Barbie Visited Biohazard Lab With RFK Jr. Before Hospitalization
Kristi Noem was hospitalized for an allergic reaction one day after Robert F. Kennedy Jr. shared a photo of them both visiting a biosafety lab that was temporarily shut down due to safety concerns. 'With @Sec_Noem and @SenRandPaul inspecting the biological hazard labs at Fort Detrick,' the Health and Human Services Secretary posted, sharing an image of himself with Noem and GOP Sen. Rand Paul at the Integrated Research Facility in Frederick, Maryland. On Tuesday, Noem was taken to the hospital by ambulance for an 'allergic reaction,' DHS' Assistant Secretary for Public Affairs Tricia McLaughlin told the Daily Beast in a statement. 'She was transported to the hospital out of an abundance of caution. She is alert and recovering,' McLaughlin said. It's not clear what prompted the allergic reaction, and there's nothing to suggest the incident was anything more than a bizarre coincidence. Noem is yet to comment on her condition publicly. The Integrated Research Facility at Fort Detrick studies viruses 'causing high-consequence disease' such as Ebola and SARS-CoV-2, according to its site. One of its focus areas is to 'mitigate major public health events related to emerging or reemerging infectious diseases or biological weapons attacks.' The MAHA Institute, a think tank supporting Kennedy's 'Make America Healthy Again' agenda, posted on X earlier that Noem, Paul, and Kennedy had toured the National Institute of Allergy and Infectious Diseases biosecurity lab at Fort Detrick on Monday. The offices of Noem, Paul and Kennedy did not immediately return requests for comment. Kennedy's department ordered an indefinite work stoppage at the lab in April. A spokesperson for NIH told WIRED at the time that the safety stand-down 'follows identification and documentation of personnel issues involving contract staff that compromised the facility's safety culture.' An unnamed HHS official told Fox News the incident stemmed from a 'lover's spat' between researchers at the facility, which allegedly resulted in one of the people poking holes in the other's personal protective equipment. Kennedy told a Senate committee in May the FBI was investigating it as a potentially 'deliberate criminal act' because the pathogens the individuals were handling were highly dangerous. He said he intended to visit the facility with Noem. Democrats last week pressed Kennedy's office for more answers on the research pause, noting that scientists at the Integrated Research Facility 'study some of the most dangerous pathogens and viruses to prevent, address, and eradicate high-consequence and deadly diseases,' and that safety measures there 'are of the utmost importance for our constituents in the surrounding communities.' The letter also asked for a timeline on when work at the labs would resume.
